X
[{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Multiverse Investment Fund Announces Portfolio Company\u2019s Commencement of Clinical Trials to Treat ARDS Caused by Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orbsen Therapeutics Announces Encouraging Interim Results from The NEPHSTROM Proof of Concept Clinical Study Evaluating Orbcel\u2122 Cell Therapy in Patients with Diabetes and Advanced Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"IRELAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Orbsen Therapeutics
Filters
Companies By Therapeutic Area
Details:
ORBCEL-M is a proprietary formulation of highly purified immunomodulatory stromal cells. It is being developed for adult subjects with type 2 diabetes and progressive diabetic kidney disease (DKD).
Lead Product(s):
Mesenchymal Stromal Cell
Therapeutic Area: Nephrology
Product Name: ORBCEL-M
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 26, 2023
Details:
Orbsen Therapeutics’ proprietary ORBCEL cellular therapy demonstrated the ability to mitigate the effects of ARDS by improving lung oxygenation.
Lead Product(s):
Allogeneic umbilical cord-derived mesenchymal stromal cell
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 15, 2020